Which has higher earnings and valuation, CELC or SVRA?

Celcuity is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is CELC or SVRA more profitable?

Savara's return on equity of -90.28% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Savara N/A -90.28% -68.95%

Does the media prefer CELC or SVRA?

In the previous week, Celcuity had 11 more articles in the media than Savara. MarketBeat recorded 26 mentions for Celcuity and 15 mentions for Savara. Celcuity's average media sentiment score of 0.13 beat Savara's score of -0.25 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 5 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Savara 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is RLAY or SVRA more profitable?

Relay Therapeutics' return on equity of -42.27% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Savara N/A -90.28% -68.95%

Does the media favor RLAY or SVRA?

In the previous week, Savara had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 15 mentions for Savara and 13 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.84 beat Savara's score of -0.25 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Savara 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ELVN or SVRA?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is ELVN or SVRA more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Savara N/A -90.28% -68.95%

Does the media favor ELVN or SVRA?

In the previous week, Enliven Therapeutics and Enliven Therapeutics both had 15 articles in the media. Enliven Therapeutics' average media sentiment score of 1.04 beat Savara's score of -0.25 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, SVRA or PBLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Is SVRA or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Parabilis Medicines N/A N/A N/A

Does the media favor SVRA or PBLS?

In the previous week, Savara had 7 more articles in the media than Parabilis Medicines. MarketBeat recorded 15 mentions for Savara and 8 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.01 beat Savara's score of -0.25 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SVRA or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Savara. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Telix Pharmaceuticals $803.79M 5.12 -$7.12M N/A N/A

Is SVRA or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Telix Pharmaceuticals N/A N/A N/A

Does the media favor SVRA or TLX?

In the previous week, Savara had 10 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 15 mentions for Savara and 5 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.49 beat Savara's score of -0.25 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Telix Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Savara (SVRA) Competitors

$5.58 +0.21 (+3.91%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$5.77 +0.19 (+3.48%)

As of 06:16 AM Eastern

Compare

SVRA vs. CELC, RLAY, ELVN, PBLS, and TLX

Should you buy Savara stock or one of its competitors? Savara's main competitors and comparable companies include Celcuity (CELC), Relay Therapeutics (RLAY), Enliven Therapeutics (ELVN), Parabilis Medicines (PBLS), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Savara compare to Celcuity?

Celcuity (NASDAQ:CELC) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Savara's return on equity of -90.28% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Savara	N/A	-90.28%	-68.95%

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Celcuity had 11 more articles in the media than Savara. MarketBeat recorded 26 mentions for Celcuity and 15 mentions for Savara. Celcuity's average media sentiment score of 0.13 beat Savara's score of -0.25 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	5 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Savara	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Celcuity is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Celcuity presently has a consensus target price of $154.55, indicating a potential upside of 65.05%. Savara has a consensus target price of $10.14, indicating a potential upside of 81.77%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Celcuity has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, Savara has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Summary

Savara beats Celcuity on 9 of the 14 factors compared between the two stocks.

How does Savara compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Relay Therapeutics presently has a consensus price target of $25.83, suggesting a potential upside of 24.56%. Savara has a consensus price target of $10.14, suggesting a potential upside of 81.77%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Relay Therapeutics' return on equity of -42.27% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Savara	N/A	-90.28%	-68.95%

In the previous week, Savara had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 15 mentions for Savara and 13 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.84 beat Savara's score of -0.25 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Savara has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	296.09	-$276.48M	-$1.57	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Savara has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Summary

Relay Therapeutics beats Savara on 8 of the 15 factors compared between the two stocks.

How does Savara compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Savara (NASDAQ:SVRA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Enliven Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Savara has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Enliven Therapeutics presently has a consensus target price of $75.00, suggesting a potential upside of 26.28%. Savara has a consensus target price of $10.14, suggesting a potential upside of 81.77%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Enliven Therapeutics' return on equity of -18.55% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Savara	N/A	-90.28%	-68.95%

In the previous week, Enliven Therapeutics and Enliven Therapeutics both had 15 articles in the media. Enliven Therapeutics' average media sentiment score of 1.04 beat Savara's score of -0.25 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Savara beats Enliven Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Savara compare to Parabilis Medicines?

Savara (NASDAQ:SVRA) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Savara presently has a consensus price target of $10.14, suggesting a potential upside of 81.77%. Parabilis Medicines has a consensus price target of $41.67, suggesting a potential upside of 0.84%. Given Savara's higher possible upside, analysts clearly believe Savara is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Parabilis Medicines	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Savara had 7 more articles in the media than Parabilis Medicines. MarketBeat recorded 15 mentions for Savara and 8 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.01 beat Savara's score of -0.25 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Parabilis Medicines' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Parabilis Medicines	N/A	N/A	N/A

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Summary

Savara beats Parabilis Medicines on 5 of the 9 factors compared between the two stocks.

How does Savara compare to Telix Pharmaceuticals?

Savara (NASDAQ:SVRA) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Savara has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Savara.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Telix Pharmaceuticals	$803.79M	5.12	-$7.12M	N/A	N/A

In the previous week, Savara had 10 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 15 mentions for Savara and 5 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.49 beat Savara's score of -0.25 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Telix Pharmaceuticals	N/A	N/A	N/A

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Savara presently has a consensus target price of $10.14, indicating a potential upside of 81.77%. Telix Pharmaceuticals has a consensus target price of $20.40, indicating a potential upside of 68.32%. Given Savara's stronger consensus rating and higher probable upside, equities analysts clearly believe Savara is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Summary

Savara beats Telix Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.10B	$3.87B	$7.16B	$12.86B
Dividend Yield	N/A	3.66%	2.55%	10.29%
P/E Ratio	-9.62	11.71	268.96	24.23
Price / Sales	N/A	1,357.03	626.47	101.69
Price / Cash	N/A	102.56	78.23	52.73
Price / Book	7.97	16.99	13.16	6.25
Net Income	-$118.84M	-$12.52M	$3.47B	$348.04M
7 Day Performance	5.88%	4.52%	2.27%	-0.17%
1 Month Performance	1.64%	7.87%	5.35%	2.66%
1 Year Performance	80.58%	63.80%	29.21%	21.01%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	1.8719 of 5 stars	$5.58 +3.9%	$10.14 +81.8%	+83.0%	$1.10B	N/A	N/A	20
CELC Celcuity	3.3694 of 5 stars	$90.98 +0.2%	$155.18 +70.6%	+90.2%	$4.46B	N/A	N/A	40	Earnings Report Analyst Forecast Gap Up
RLAY Relay Therapeutics	3.2959 of 5 stars	$20.03 +0.5%	$25.58 +27.7%	+510.0%	$4.40B	$15.35M	N/A	330	Gap Up
ELVN Enliven Therapeutics	3.3274 of 5 stars	$58.14 -2.2%	$72.67 +25.0%	+200.6%	$4.27B	N/A	N/A	50	Analyst Forecast Insider Trade
PBLS Parabilis Medicines	1.8807 of 5 stars	$35.84 +0.3%	$41.67 +16.3%	N/A	$4.23B	N/A	N/A	N/A	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. CELC, RLAY, ELVN, PBLS, and TLX

How does Savara compare to Celcuity?

Summary

How does Savara compare to Relay Therapeutics?

Summary

How does Savara compare to Enliven Therapeutics?

Summary

How does Savara compare to Parabilis Medicines?

Summary

How does Savara compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. CELC, RLAY, ELVN, PBLS, and TLX

How does Savara compare to Celcuity?

Is CELC or SVRA more profitable?

Do insiders & institutionals have more ownership in CELC or SVRA?

Does the media prefer CELC or SVRA?

Which has higher earnings and valuation, CELC or SVRA?

Do analysts prefer CELC or SVRA?

Which has more volatility and risk, CELC or SVRA?

Summary

How does Savara compare to Relay Therapeutics?

Do analysts recommend RLAY or SVRA?

Is RLAY or SVRA more profitable?

Does the media favor RLAY or SVRA?

Do institutionals and insiders have more ownership in RLAY or SVRA?

Which has stronger valuation & earnings, RLAY or SVRA?

Which has more risk and volatility, RLAY or SVRA?

Summary

How does Savara compare to Enliven Therapeutics?

Which has more volatility & risk, ELVN or SVRA?

Do institutionals & insiders have more ownership in ELVN or SVRA?

Which has stronger earnings & valuation, ELVN or SVRA?

Do analysts prefer ELVN or SVRA?

Is ELVN or SVRA more profitable?

Does the media favor ELVN or SVRA?

Summary

How does Savara compare to Parabilis Medicines?

Do analysts recommend SVRA or PBLS?

Does the media favor SVRA or PBLS?

Is SVRA or PBLS more profitable?

Do insiders & institutionals have more ownership in SVRA or PBLS?

Which has higher earnings & valuation, SVRA or PBLS?

Summary

How does Savara compare to Telix Pharmaceuticals?

Which has more volatility & risk, SVRA or TLX?

Which has preferable valuation & earnings, SVRA or TLX?

Does the media favor SVRA or TLX?

Is SVRA or TLX more profitable?

Do institutionals & insiders hold more shares of SVRA or TLX?

Do analysts rate SVRA or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools